Ben Sousa Sells 2,250 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) insider Ben Sousa sold 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the transaction, the insider directly owned 3,076 shares in the company, valued at $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ICU Medical Stock Down 1.5%

ICUI stock traded down $2.74 during midday trading on Wednesday, reaching $179.34. The company had a trading volume of 314,014 shares, compared to its average volume of 297,162. The company has a 50 day moving average of $153.69 and a two-hundred day moving average of $141.31. The company has a market capitalization of $4.48 billion, a P/E ratio of 151.98, a PEG ratio of 2.55 and a beta of 0.74. ICU Medical, Inc. has a 1 year low of $110.50 and a 1 year high of $192.85. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. ICU Medical’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities research analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ICUI. KeyCorp increased their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Needham & Company LLC lifted their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and an average target price of $192.80.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors have recently modified their holdings of ICUI. Emerald Investment Advisers LLC bought a new stake in shares of ICU Medical during the 2nd quarter worth $3,711,000. William Blair Investment Management LLC acquired a new position in ICU Medical during the 2nd quarter worth $25,242,000. Ieq Capital LLC acquired a new position in ICU Medical during the 2nd quarter worth $906,000. Allworth Financial LP bought a new stake in ICU Medical during the second quarter valued at about $26,000. Finally, Madison Asset Management LLC bought a new stake in ICU Medical during the second quarter valued at about $2,652,000. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.